Landos Biopharma, Inc.
LABP · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $23 | $20 | $193 | $481 |
| - Cash | $38 | $37 | $8 | $2 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$15 | -$17 | $185 | $479 |
| Revenue | $0 | $0 | $18 | $0 |
| % Growth | – | -100% | – | – |
| Gross Profit | $0 | -$1 | $18 | -$0 |
| % Margin | – | – | 98.9% | – |
| EBITDA | -$23 | -$39 | -$39 | -$30 |
| % Margin | – | – | -214.6% | – |
| Net Income | -$22 | -$38 | -$38 | -$30 |
| % Margin | – | – | -212.4% | – |
| EPS Diluted | -3.5 | -9.44 | -9.5 | -7.51 |
| % Growth | 62.9% | 0.6% | -26.5% | – |
| Operating Cash Flow | -$20 | -$46 | -$27 | -$23 |
| Capital Expenditures | $0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$20 | -$46 | -$28 | -$23 |